Jean De Serres

Feldan is a biopharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan designed a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. The Shuttle technology unlocks the development of a new generation of therapies by giving access to intracellular components beyond the reach of existing drugs. Feldan's pipeline focuses on diseases affecting skin and lungs. Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the development of the Feldan Shuttle, this approach is starting to show its promises.

Created in 1983, the Fonds de solidarité FTQ is a development capital fund that calls upon the solidarity and savings of Quebecers to help fulfill its mission to contribute to Québecs economic growth by creating, maintain or protecting jobs through investments in small and medium-sized businesses in all spheres of activity. The Fonds also seeks to encourage Quebecers to save for retirement and to offer its over half a million shareholders-savers a reasonable return over and above the outstanding tax benefits they receive by purchasing Fonds shares. The largest development capital network in the province, the Fonds de solidarité FTQ was created on the initiative of the FTQ, Québec’s largest central labour body. Through its governance and codes of ethics, the Fonds is a socially responsible investor committed to sustainable economic development where people come first. Aside from investing capital, the Fonds is committed to supporting the growth of its partner companies by offering value-added services such as economic training. With net assets of $13.8 billion as at May 31, 2020, the Fonds de solidarité FTQ has become a hub of knowledge and resources for Québec businesses and a key player in the local economy.

Feldan is a biopharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan designed a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. The Shuttle technology unlocks the development of a new generation of therapies by giving access to intracellular components beyond the reach of existing drugs. Feldan's pipeline focuses on diseases affecting skin and lungs. Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the development of the Feldan Shuttle, this approach is starting to show its promises.